mTOR pathway activation heterogeneous in kidney tumors

Article

Using tissue samples from primary renal tumors and matching resected or biopsied metastatic deposits, researchers reported new insights into determining which patients may benefit most from such mTOR inhibitors as temsirolimus (Torisel) and everolimus (Afinitor).

Washington-The mTOR/p70S6 kinase pathway is an important element of carcinogenesis in renal cell carcinoma, and its inhibition is often helpful in treating patients with advanced disease. But clinicians find that not all patients respond to mTOR inhibitors, raising the question of exactly which types of tumors are best treated with those agents.

Using tissue samples from primary renal tumors and matching resected or biopsied metastatic deposits, first author Alexander Kutikov, MD, and colleagues reported new insights into determining which patients may benefit most from such mTOR inhibitors as temsirolimus (Torisel) and everolimus (Afinitor).

Related Videos
Lab with MRI machine | Image Credit: © phonlamaiphoto - stock.adobe.com
Abstract blur luxury hospital corridor | Image Credit: @ zephyr_p - @ zephyr_p - stock.adobe.com
Anne M. Suskind, MD, MS, FACS, FPMRS, answers a question during a Zoom video interview
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Peter N. Tsambarlis, MD, answers a question during a Zoom video interview
Illustration of Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.